Rein Therapeutics completed a $57.5 million underwritten public offering by selling 57.5 million shares at $1.00 each, including the full exercise of an over-allotment option. The proceeds will fund the Phase 2 clinical trial of their drug LTI-03 for idiopathic pulmonary fibrosis (IPF) through completion and support operations into 2028. The company expects this funding, combined with existing cash, to sustain operations until early 2028. This financing strengthens Rein's position to advance its clinical and regulatory activities for orphan pulmonary and fibrosis treatments.
Streamex Corp. announced its second monthly yield distribution for GLDY, a gold-backed tokenized security, covering April 2026. The yield is generated through Streamex's institutional gold leasing program, which currently earns an annualized lease yi...
TOYO Co., Ltd announced a 177% increase in Q1 2026 revenue to $142.8 million, driven by higher solar cell and module sales. Net income rose to $28.4 million from a loss of $3.7 million in Q1 2025, with EBITDA improving significantly. The company reaf...
IREN Limited has acquired Awaken, a creative and media agency, to strengthen its brand awareness and marketing as it expands globally. Awaken, previously IREN's external marketing partner, will now operate in-house with key team members, including CE...
Sitryx Therapeutics, a clinical-stage biopharmaceutical company focused on autoimmune and inflammatory diseases, announced its management will participate in three key investor conferences in June 2026: Jefferies Global Healthcare Conference in New Y...
Regeneron Pharmaceuticals' stock fell over 10% following the Phase 3 trial results for their melanoma treatment combining fianlimab and cemiplimab. The trial did not achieve statistical significance for the primary endpoint of progression-free surviv...
